Journal article icon

Journal article

APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease

Abstract:

Background

Aggregation of amyloid β into plaques in the brain is one of the earliest pathological events in Alzheimer's disease (AD). The exact pathophysiology leading to dementia is still uncertain, but the apolipoprotein E (APOE) ε4 genotype plays a major role. We aimed to identify the molecular pathways associated with amyloid β aggregation using cerebrospinal fluid (CSF) proteomics and to study the potential modifying effects of APOE ε4 genotype.

Methods

We tested 243 proteins and protein fragments in CSF comparing 193 subjects with AD across the cognitive spectrum (65% APOE ε4 carriers, average age 75 ± 7 years) against 60 controls with normal CSF amyloid β, normal cognition, and no APOE ε4 allele (average age 75 ± 6 years).

Results

One hundred twenty-nine proteins (53%) were associated with aggregated amyloid β. APOE ε4 carriers with AD showed altered concentrations of proteins involved in the complement pathway and glycolysis when cognition was normal and lower concentrations of proteins involved in synapse structure and function when cognitive impairment was moderately severe. APOE ε4 non-carriers with AD showed lower expression of proteins involved in synapse structure and function when cognition was normal and lower concentrations of proteins that were associated with complement and other inflammatory processes when cognitive impairment was mild. Repeating analyses for 114 proteins that were available in an independent EMIF-AD MBD dataset (n = 275) showed that 80% of the proteins showed group differences in a similar direction, but overall, 28% effects reached statistical significance (ranging between 6 and 87% depending on the disease stage and genotype), suggesting variable reproducibility.

Conclusions

These results imply that AD pathophysiology depends on APOE genotype and that treatment for AD may need to be tailored according to APOE genotype and severity of the cognitive impairment.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Publisher copy:
10.1186/s13195-020-00628-z

Authors

More by this author
Role:
Author
ORCID:
0000-0002-2962-2941
More by this author
Role:
Author
ORCID:
0000-0002-2612-1797
More by this author
Role:
Author
ORCID:
0000-0001-6193-6193
More by this author
Role:
Author
ORCID:
0000-0001-8559-1097
More by this author
Role:
Author
ORCID:
0000-0001-9648-6428


Publisher:
BioMed Central
Journal:
Alzheimer's Research & Therapy More from this journal
Volume:
12
Issue:
1
Pages:
65-65
Article number:
ARTN 65
Publication date:
2020-05-27
Acceptance date:
2020-05-06
DOI:
EISSN:
1758-9193
ISSN:
1758-9193


Language:
English
Keywords:
Pubs id:
1110163
Local pid:
pubs:1110163
Source identifiers:
W3030424674
Deposit date:
2026-08-14
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP